Turner, N. C., Kalinsky, K., Hutchinson, K. E., Jin, Y., Clark, T. D., Jhaveri, K. L., Loibl, S., Manich, C. S., Desmedt, C., Wildiers, H., Im, S., Neven, P., Schmid, P., Juric, D., Loi, S., Hilz, S., Stout, T. J. (2026). Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with PIK3CA -mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1079